Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076409 | 0.93 | ADORA1 (0.35) | C5AR1ADORA1F12MAPTGRAMD1A | |
| SCHEMBL2075842 | 0.83 | C5AR1 (0.47) | C5AR1F12MAPTESR2 | |
| SCHEMBL2076531 | 0.83 | C5AR1 (0.33) | C5AR1ADORA1 | |
| SCHEMBL6027740 | 0.83 | CXCR2 (0.32) | ADORA1 | |
| SCHEMBL2075815 | 0.82 | MAPT (0.32) | MAPTGRAMD1A | |
| SCHEMBL2074189 | 0.82 | ADORA1 (0.34) | C5AR1ADORA1DDB1CRBN | |
| SCHEMBL2076338 | 0.81 | ADORA1 (0.33) | ADORA1MAPTDDB1CRBN | |
| SCHEMBL18493654 | 0.80 | MAPT (0.47) | C5AR1MAPT | |
| SCHEMBL2075276 | 0.79 | NR1H2 (0.31) | NR1H2 | |
| SCHEMBL25796716 | 0.79 | C5AR1 (0.41) | C5AR1ADORA1F12MAPTGRAMD1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | C5AR1 2550/4885ADORA1 862/4885F12 3605/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | C5AR1 2550/4885ADORA1 862/4885F12 3605/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | C5AR1 2550/4885ADORA1 862/4885F12 3605/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | C5AR1 2550/4885ADORA1 862/4885F12 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.